表紙
市場調查報告書
商品編碼
975687

全球HIV藥品市場規模調查:按藥品類別和地區進行的預測(2020-2027)

Global HIV Drugs Market Size study, By Medication Class, and Regional Forecasts 2020-2027

出版日期: | 出版商: Bizwit Research & Consulting LLP | 英文 | 商品交期: 2-3個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

2019年,全球HIV藥品市場約為309億美元。預計到2020年至2027年,市場將以4.3%的健康增長率增長。

人類免疫缺陷病毒(HIV)是一種慢性且危及生命的疾病,可以通過血液接觸或性接觸在人與人之間傳播。它是一種病毒,會破壞稱為CD-4細胞的免疫細胞,並使人體容易感染和其他疾病。多年來,愛滋病毒感染在世界範圍內的傳播對愛滋病毒藥物的需求產生了積極影響。艾滋病毒藥物有助於防止愛滋病毒的傳播,並減少愛滋病毒傳播的風險。

推動HIV藥品市場增長的關鍵因素包括較高的HIV陽性率以及較高的護理和診斷率。此外,政府越來越多地採取主動行動,以提高公眾對病因,症狀,可用的治療選擇以及這些治療在控制HIV病毒生長中的重要作用的認識。結果,通過這些政府計劃提高認識也有望改善對愛滋病毒藥物的需求。

但是,嚴格的政府法規對HIV藥品的批准和銷售可能會限制HIV藥品行業的發展。導致患病率上升的因素包括不安全的性行為,被感染的針頭或註射器以及對感染方式的瞭解不足。政府和各種非政府組織的合作努力,使處於危險中的人接受疾病檢查,並擴大對感染者的照顧,這是推動HIV-1產業發展的重要動力。此外,具有成本效益的化學品牌仿製藥的出現是對HIV藥物需求增加的另一個因素。根據世界衛生組織的數據,2018年全球3790萬人被診斷出患有HIV/愛滋病,同年有110萬人死於與愛滋病有關的疾病。聯邦機構和世界各地的許多組織已經發起了各種社區宣傳計劃和教育運動,以促進愛滋病毒的預防,治療和護理。

該報告調查了全球HIV藥品市場,並概述了該市場,按藥品類別和地區劃分的趨勢以及進入該市場的公司的概況。

目錄

第1章執行摘要

第2章全球HIV藥品市場的定義和範圍

  • 調查目的
  • 市場定義和範圍
    • 調查範圍
    • 行業發展
  • 調查對像年度
  • 匯率

第3章全球HIV藥品市場動態

  • HIV藥品市場的影響分析(2018-2027)

第4章全球HIV藥品市場:行業分析

  • 波特的五力模型
  • PEST分析
  • 投資採用模型
  • 分析師的建議和結論

第5章,按藥品類別劃分的全球HIV藥品市場

  • 市場概況
  • 全球愛滋病毒藥品市場:按藥品類別,性能潛力分析
  • 全球HIV藥物市場估計和預測:按藥物類別分,2017-2027(10億美元)
  • HIV藥品市場細分分析
    • 多類伴隨藥物
    • 核甘逆轉錄□抑製劑(NRTI)
    • 非核甘逆轉錄□抑製劑(NNRTI)
    • 蛋白□抑□□製劑(P0I)
    • 入侵抑製劑
    • HIV整合□鏈轉移抑製劑

第6章,全球HIV藥品市場,區域分析

  • 區域市場概況
  • 北美
    • 美國
    • 加拿大
  • 歐洲快照
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 意大利
    • 其他
  • 亞太地區快照
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 韓國
    • 其他
  • 拉丁美洲快照
    • 巴西
    • 墨西哥
  • 其他

第7章競爭信息

  • 頂級市場策略
  • 公司簡介
    • Boehringer Ingelheim International GmbH
    • Merck & Co., Inc.
    • ViiV Healthcare
    • AbbVie
    • F. Hoffmann-La Roche Ltd.
    • Teva Pharmaceutical Industries Ltd.
    • Bristol-Myers Squibb
    • Gilead Sciences, Inc.
    • Johnson & Johnson
    • Cipla Limited
    • Daiichi Sankyo
    • Emcure
    • Hetero Drugs
    • Mylan

第8章調查流程

目錄

Title:
Global HIV Drugs Market Size study, By Medication Class (Multi-class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Entry Inhibitors, and HIV Integrase Strand Transfer Inhibitors), and Regional Forecasts 2020-2027.

Global HIV Drugs Market is valued approximately at USD 30.9 billion in 2019 and is anticipated to grow with a healthy growth rate of more than 4.3% over the forecast period 2020-2027. Human Immunodeficiency Virus (HIV) is a chronic and life-threatening disease that can be transmitted from one person to another through blood-to-blood and sexual contact. It is a virus that destroys immune cells known as CD-4 cells, rendering the body vulnerable to infections and other diseases. Over the years, the growing prevalence of HIV disease worldwide has had a positive effect on demand for HIV drugs. HIV medications help prevent the spread of HIV, thereby reducing the risk of transmission of HIV. Significant factors that fuel the growth of the HIV drug market include an increase in HIV prevalence and an increase in the rate of care and diagnosis. In addition, there is an increase in government initiatives to raise awareness among people about the cause of HIV, symptoms, available treatment options, and the critical role of these treatments in controlling the growth of the HIV virus. As a result, awareness-raising through such government programs is also expected to improve the demand for HIV drugs. However, strict government regulations for the approval and sale of HIV drugs are likely to limit the development of the HIV drug industry. The factors responsible for increasing prevalence include unsafe sex, infected needles or syringes, and, lack of knowledge of the mode of transmission. The concerted efforts of the government and various NGOs to provide at-risk individuals with greater exposure to disease testing and care for infected persons are a key driver of the growth of the HIV-1 industry. In addition, the advent of generic drugs, which are cost-effective and chemically like branded drugs, is another factor adding to the demand for HIV drugs. According to WHO, 37.9 million people were diagnosed with HIV/AIDS in 2018, globally, while 1.1 million died of AIDS-related illness in the same year. A variety of community awareness programmes and education campaigns have been initiated by federal government agencies and numerous organizations across the globe to combat HIV prevention, treatment and care.

The regional analysis of global HIV Drugs Market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America, and Rest of the World. Asia-Pacific offers lucrative prospects for key players on the HIV drug market due to a rise in population and a high increase in geriatric population. In addition, the increase in health expenditure and the production of guidelines are expected to fuel market growth in the region.

Major market player included in this report are:

  • Boehringer Ingelheim International GmbH
  • Merck & Co., Inc.
  • ViiV Healthcare
  • AbbVie
  • F. Hoffmann-La Roche Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Bristol-Myers Squibb
  • Gilead Sciences, Inc.
  • Johnson & Johnson
  • Cipla Limited
  • Daiichi Sankyo
  • Emcure
  • Hetero Drugs
  • Mylan

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Medication Class:

  • Multi-class Combination Drugs
  • Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
  • Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
  • Protease Inhibitors (P0Is)
  • Entry Inhibitors
  • HIV Integrase Strand Transfer Inhibitors

By Region:

  • North America
  • U.S.
  • Canada
  • Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • ROE
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • RoAPAC
  • Latin America
  • Brazil
  • Mexico
  • Rest of the World

Furthermore, years considered for the study are as follows:

  • Historical year - 2017, 2018
  • Base year - 2019
  • Forecast period - 2020 to 2027

Target Audience of the Global HIV Drugs Market in Market Study:

  • Key Consulting Companies & Advisors
  • Large, medium-sized, and small enterprises
  • Venture capitalists
  • Value-Added Resellers (VARs)
  • Third-party knowledge providers
  • Investment bankers
  • Investors

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2018-2027 (USD Billion)
    • 1.2.1. HIV Drugs Market, by Region, 2018-2027 (USD Billion)
    • 1.2.2. HIV Drugs Market, by Medication Class, 2018-2027 (USD Billion)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global HIV Drugs Market Definition & Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Scope of the Study
    • 2.2.2. Industry Evolution
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global HIV Drugs Market Dynamics

  • 3.1. HIV Drugs Market Impact Analysis (2018-2027)
    • 3.1.1. Market Drivers
    • 3.1.2. Market Challenges
    • 3.1.3. Market Opportunities

Chapter 4. Global HIV Drugs Market: Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
    • 4.1.6. Futuristic Approach to Porter's 5 Force Model (2017-2027)
  • 4.2. PEST Analysis
    • 4.2.1. Political
    • 4.2.2. Economical
    • 4.2.3. Social
    • 4.2.4. Technological
  • 4.3. Investment Adoption Model
  • 4.4. Analyst Recommendation & Conclusion

Chapter 5. Global HIV Drugs Market, by Medication Class

  • 5.1. Market Snapshot
  • 5.2. Global HIV Drugs Market by Medication Class, Performance - Potential Analysis
  • 5.3. Global HIV Drugs Market Estimates & Forecasts by Medication Class, 2017-2027 (USD Billion)
  • 5.4. HIV Drugs Market, Sub Segment Analysis
    • 5.4.1. Multi-class Combination Drugs
    • 5.4.2. Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
    • 5.4.3. Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
    • 5.4.4. Protease Inhibitors (P0Is)
    • 5.4.5. Entry Inhibitors
    • 5.4.6. HIV Integrase Strand Transfer Inhibitors

Chapter 6. Global HIV Drugs Market, Regional Analysis

  • 6.1. HIV Drugs Market, Regional Market Snapshot
  • 6.2. North America HIV Drugs Market
    • 6.2.1. U.S. HIV Drugs Market
      • 6.2.1.1. Medication Class breakdown estimates & forecasts, 2017-2027
    • 6.2.2. Canada HIV Drugs Market
  • 6.3. Europe HIV Drugs Market Snapshot
    • 6.3.1. U.K. HIV Drugs Market
    • 6.3.2. Germany HIV Drugs Market
    • 6.3.3. France HIV Drugs Market
    • 6.3.4. Spain HIV Drugs Market
    • 6.3.5. Italy HIV Drugs Market
    • 6.3.6. Rest of Europe HIV Drugs Market
  • 6.4. Asia-Pacific HIV Drugs Market Snapshot
    • 6.4.1. China HIV Drugs Market
    • 6.4.2. India HIV Drugs Market
    • 6.4.3. Japan HIV Drugs Market
    • 6.4.4. Australia HIV Drugs Market
    • 6.4.5. South Korea HIV Drugs Market
    • 6.4.6. Rest of Asia Pacific HIV Drugs Market
  • 6.5. Latin America HIV Drugs Market Snapshot
    • 6.5.1. Brazil HIV Drugs Market
    • 6.5.2. Mexico HIV Drugs Market
  • 6.6. Rest of The World HIV Drugs Market

Chapter 7. Competitive Intelligence

  • 7.1. Top Market Strategies
  • 7.2. Company Profiles
    • 7.2.1. Boehringer Ingelheim International GmbH
      • 7.2.1.1. Key Information
      • 7.2.1.2. Overview
      • 7.2.1.3. Financial (Subject to Data Availability)
      • 7.2.1.4. Industry Summary
      • 7.2.1.5. Recent Developments
    • 7.2.2. Merck & Co., Inc.
    • 7.2.3. ViiV Healthcare
    • 7.2.4. AbbVie
    • 7.2.5. F. Hoffmann-La Roche Ltd.
    • 7.2.6. Teva Pharmaceutical Industries Ltd.
    • 7.2.7. Bristol-Myers Squibb
    • 7.2.8. Gilead Sciences, Inc.
    • 7.2.9. Johnson & Johnson
    • 7.2.10. Cipla Limited
    • 7.2.11. Daiichi Sankyo
    • 7.2.12. Emcure
    • 7.2.13. Hetero Drugs
    • 7.2.14. Mylan

Chapter 8. Research Process

  • 8.1. Research Process
    • 8.1.1. Data Mining
    • 8.1.2. Analysis
    • 8.1.3. Market Estimation
    • 8.1.4. Validation
    • 8.1.5. Publishing
  • 8.2. Research Attributes
  • 8.3. Research Assumption

LIST OF TABLES

  • TABLE 1. GLOBAL HIV DRUGS MARKET, REPORT SCOPE
  • TABLE 2. GLOBAL HIV DRUGS MARKET ESTIMATES & FORECASTS BY REGION 2017-2027 (USD BILLION)
  • TABLE 3. GLOBAL HIV DRUGS MARKET ESTIMATES & FORECASTS BY MEDICATION CLASS 2017-2027 (USD BILLION)
  • TABLE 4. GLOBAL HIV DRUGS MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
  • TABLE 5. GLOBAL HIV DRUGS MARKET BY REGION, ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
  • TABLE 6. GLOBAL HIV DRUGS MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
  • TABLE 7. GLOBAL HIV DRUGS MARKET BY REGION, ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
  • TABLE 8. GLOBAL HIV DRUGS MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
  • TABLE 9. GLOBAL HIV DRUGS MARKET BY REGION, ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
  • TABLE 10. GLOBAL HIV DRUGS MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
  • TABLE 11. GLOBAL HIV DRUGS MARKET BY REGION, ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
  • TABLE 12. GLOBAL HIV DRUGS MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
  • TABLE 13. GLOBAL HIV DRUGS MARKET BY REGION, ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
  • TABLE 14. U.S. HIV DRUGS MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
  • TABLE 15. U.S. HIV DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 16. U.S. HIV DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 17. CANADA HIV DRUGS MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
  • TABLE 18. CANADA HIV DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 19. CANADA HIV DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 20. UK HIV DRUGS MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
  • TABLE 21. UK HIV DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 22. UK HIV DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 23. GERMANY HIV DRUGS MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
  • TABLE 24. GERMANY HIV DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 25. GERMANY HIV DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 26. ROE HIV DRUGS MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
  • TABLE 27. ROE HIV DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 28. ROE HIV DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 29. CHINA HIV DRUGS MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
  • TABLE 30. CHINA HIV DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 31. CHINA HIV DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 32. INDIA HIV DRUGS MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
  • TABLE 33. INDIA HIV DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 34. INDIA HIV DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 35. JAPAN HIV DRUGS MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
  • TABLE 36. JAPAN HIV DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 37. JAPAN HIV DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 38. ROAPAC HIV DRUGS MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
  • TABLE 39. ROAPAC HIV DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 40. ROAPAC HIV DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 41. BRAZIL HIV DRUGS MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
  • TABLE 42. BRAZIL HIV DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 43. BRAZIL HIV DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 44. MEXICO HIV DRUGS MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
  • TABLE 45. MEXICO HIV DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 46. MEXICO HIV DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 47. ROLA HIV DRUGS MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
  • TABLE 48. ROLA HIV DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 49. ROLA HIV DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 50. ROW HIV DRUGS MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
  • TABLE 51. ROW HIV DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 52. ROW HIV DRUGS MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 53. LIST OF SECONDARY SOURCES, USED IN THE STUDY OF GLOBAL HIV DRUGS MARKET
  • TABLE 54. LIST OF PRIMARY SOURCES, USED IN THE STUDY OF GLOBAL HIV DRUGS MARKET
  • TABLE 55. YEARS CONSIDERED FOR THE STUDY
  • TABLE 56. EXCHANGE RATES CONSIDERED

LIST OF FIGURES

  • FIG 1. GLOBAL HIV DRUGS MARKET, RESEARCH METHODOLOGY
  • FIG 2. GLOBAL HIV DRUGS MARKET, MARKET ESTIMATION TECHNIQUES
  • FIG 3. GLOBAL MARKET SIZE ESTIMATES & FORECAST METHODS
  • FIG 4. GLOBAL HIV DRUGS MARKET, KEY TRENDS 2019
  • FIG 5. GLOBAL HIV DRUGS MARKET, GROWTH PROSPECTS 2020-2027
  • FIG 6. GLOBAL HIV DRUGS MARKET, PORTERS 5 FORCE MODEL
  • FIG 7. GLOBAL HIV DRUGS MARKET, PEST ANALYSIS
  • FIG 8. GLOBAL HIV DRUGS MARKET, VALUE CHAIN ANALYSIS
  • FIG 9. GLOBAL HIV DRUGS MARKET BY SEGMENT, 2017 & 2027 (USD BILLION)
  • FIG 10. GLOBAL HIV DRUGS MARKET BY SEGMENT, 2017 & 2027 (USD BILLION)
  • FIG 11. GLOBAL HIV DRUGS MARKET BY SEGMENT, 2017 & 2027 (USD BILLION)
  • FIG 12. GLOBAL HIV DRUGS MARKET BY SEGMENT, 2017 & 2027 (USD BILLION)
  • FIG 13. GLOBAL HIV DRUGS MARKET BY SEGMENT, 2017 & 2027 (USD BILLION)
  • FIG 14. GLOBAL HIV DRUGS MARKET, REGIONAL SNAPSHOT 2017 & 2027
  • FIG 15. NORTH AMERICA HIV DRUGS MARKET 2017 & 2027 (USD BILLION)
  • FIG 16. EUROPE HIV DRUGS MARKET 2017 & 2027 (USD BILLION)
  • FIG 17. ASIA PACIFIC HIV DRUGS MARKET 2017 & 2027 (USD BILLION)
  • FIG 18. LATIN AMERICA HIV DRUGS MARKET 2017 & 2027 (USD BILLION)
  • FIG 19. GLOBAL HIV DRUGS MARKET, COMPANY MARKET SHARE ANALYSIS (2019)